Polyclonal immunoglobulin

This page covers all Polyclonal immunoglobulin drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Respiratory syncytial virus (RSV) surface proteins, Histamine and mast cell stabilization, Anthrax protective antigen (PA); anthrax lethal factor (LF).

Targets

Respiratory syncytial virus (RSV) surface proteins · Histamine and mast cell stabilization · Anthrax protective antigen (PA); anthrax lethal factor (LF) · Pseudomonas aeruginosa lipopolysaccharide and surface antigens

Marketed (3)

• RSV Polyclonal Immunoglobulin · National Institute of Allergy and Infectious Diseases (NIAID) · Immunology / Infectious Disease
  RSV polyclonal immunoglobulin provides passive immunity by supplying antibodies that bind to respiratory syncytial virus and neutralize its infectivity.
• human histaglobulin · Hangzhou Grand Biologic Pharmaceutical, Inc. · Immunology; Allergy
  Human histaglobulin is a polyclonal immunoglobulin preparation that modulates immune responses by providing passive immunization and stabilizing mast cells to reduce histamine release.
• Anthrax Immune Globulin · National Institutes of Health Clinical Center (CC) · Infectious Disease; Immunology
  Anthrax Immune Globulin provides passive immunization by supplying antibodies that neutralize anthrax toxins and enhance clearance of Bacillus anthracis.

Phase 3 pipeline (1)

• IgY · Mukoviszidose Institut gGmbH · Respiratory / Infectious Disease
  IgY is a polyclonal immunoglobulin Y (chicken antibody) therapeutic that targets and neutralizes Pseudomonas aeruginosa virulence factors and biofilm components in the respiratory tract.

Patent intelligence

• polyclonal immunoglobulin patent landscape — aggregated cliff calendar, attackable patents, originator estates